Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient
NCT06241248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110
Last updated 2026-01-15
Summary
Sepsis is a serious health problem with a very high mortality in the ICU. The most important treatment for sepsis is the fastest possible antibiotic therapy. The identification of the pathogen responsible for sepsis is essential to propose an appropriate antibiotic treatment. However, the diagnosis of bacteremia by blood culture requires an average delay of 48 to 72 hours. The new test proposed by OCEAN Dx makes it possible to identify a bacteremia in a few hours. The main objective of the study is to evaluate the performance of the rapid identification test for bacteremia proposed by OCEAN Dx compared to a classic diagnostic strategy using blood cultures.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Rapid sepsis diagnostic test
The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-13
- Primary Completion
- 2025-06-10
- Completion
- 2025-06-10
Countries
- France
Study Locations
More Related Trials
-
Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis
NCT06219135 ·Status: RECRUITING
-
Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis
NCT03115125 ·Status: UNKNOWN ·Phase: NA
-
Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit
NCT06624618 ·Status: RECRUITING
-
The Clinical and Pharmacoeconomic Impact of Rapid Diagnostic Test (Multiplex PCR FilmArray) on Antimicrobial Decision Making Compared to Conventional Decision Making Among Critically Ill Patients
NCT05759494 ·Status: UNKNOWN
-
Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis
NCT01995448 ·Status: COMPLETED
-
Monocyte Distribution Width (MDW): An Early Marker of Sepsis in Patients With Comorbidities
NCT06953154 ·Status: COMPLETED
-
Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis
NCT02198950 ·Status: COMPLETED
-
Bacterial Infection Diagnosis Using Blood DNA
NCT00698919 ·Status: UNKNOWN
-
CD64 and Antibiotics in Human Sepsis
NCT02922998 ·Status: COMPLETED
-
Improving Morbidity During Post-Acute Care Transitions for Sepsis
NCT03865602 ·Status: COMPLETED ·Phase: NA
-
Relation Between Mean Arterial Pressure and Renal Resistive Index in the Early Phase of Septic Shock
NCT04281277 ·Status: COMPLETED ·Phase: NA
-
Early Optimization of Ceftazidime Regimen in Critical Care
NCT07085624 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients
NCT02446392 ·Status: COMPLETED
-
Short-course Antimicrobial Therapy in Sepsis
NCT02899143 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Parameters Collected From Routine Data for the Diagnosis of Sepsis and Septic Shock and Their Influence on Time to Diagnosis and Patient Outcome
NCT05383963 ·Status: RECRUITING
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology
NCT00791310 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department
NCT03299894 ·Status: COMPLETED ·Phase: NA
-
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
NCT03682003 ·Status: UNKNOWN
-
Evaluation of bioMarkErs to Reduce Antibiotics Use in hospitalizeD nEonates
NCT03299751 ·Status: COMPLETED ·Phase: NA
-
Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit
NCT01085994 ·Status: UNKNOWN
-
N\L Ratio Versus L\A Ratio as a Predictor of Morbidity and Mortality in Sepsis and Septic Shock
NCT05825118 ·Status: UNKNOWN
-
Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.
NCT02300415 ·Status: UNKNOWN
-
Septic Shock-induced Immunosuppression
NCT04067674 ·Status: RECRUITING
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN